RU2020106730A - Инкапсулированные полинуклеотиды и способы их применения - Google Patents

Инкапсулированные полинуклеотиды и способы их применения Download PDF

Info

Publication number
RU2020106730A
RU2020106730A RU2020106730A RU2020106730A RU2020106730A RU 2020106730 A RU2020106730 A RU 2020106730A RU 2020106730 A RU2020106730 A RU 2020106730A RU 2020106730 A RU2020106730 A RU 2020106730A RU 2020106730 A RU2020106730 A RU 2020106730A
Authority
RU
Russia
Prior art keywords
recombinant dna
dna molecule
mir
virus
cell
Prior art date
Application number
RU2020106730A
Other languages
English (en)
Russian (ru)
Other versions
RU2020106730A3 (cg-RX-API-DMAC7.html
Inventor
Митчелл Х. ФАЙНЕР
Эдвард КЕННЕДИ
Лорена Лернер
Original Assignee
Онкорус, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкорус, Инк. filed Critical Онкорус, Инк.
Publication of RU2020106730A publication Critical patent/RU2020106730A/ru
Publication of RU2020106730A3 publication Critical patent/RU2020106730A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2020106730A 2017-07-14 2018-07-13 Инкапсулированные полинуклеотиды и способы их применения RU2020106730A (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762532886P 2017-07-14 2017-07-14
US62/532,886 2017-07-14
US201862648651P 2018-03-27 2018-03-27
US62/648,651 2018-03-27
PCT/US2018/042136 WO2019014623A1 (en) 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use

Publications (2)

Publication Number Publication Date
RU2020106730A true RU2020106730A (ru) 2021-08-16
RU2020106730A3 RU2020106730A3 (cg-RX-API-DMAC7.html) 2022-05-13

Family

ID=65002120

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020106730A RU2020106730A (ru) 2017-07-14 2018-07-13 Инкапсулированные полинуклеотиды и способы их применения

Country Status (13)

Country Link
US (1) US20200224220A1 (cg-RX-API-DMAC7.html)
EP (1) EP3652325A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020530778A (cg-RX-API-DMAC7.html)
KR (1) KR20200036873A (cg-RX-API-DMAC7.html)
CN (1) CN111212914A (cg-RX-API-DMAC7.html)
AU (1) AU2018301701A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020000839A2 (cg-RX-API-DMAC7.html)
CA (1) CA3069821A1 (cg-RX-API-DMAC7.html)
IL (1) IL271969A (cg-RX-API-DMAC7.html)
MX (1) MX2020000495A (cg-RX-API-DMAC7.html)
RU (1) RU2020106730A (cg-RX-API-DMAC7.html)
SG (1) SG11202000312UA (cg-RX-API-DMAC7.html)
WO (1) WO2019014623A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020000993A (es) 2017-07-26 2020-07-22 Oncorus Inc Vectores virales oncolíticos y usos de estos.
MX2020001593A (es) 2017-08-09 2020-07-13 Bioverativ Therapeutics Inc Moleculas de acido nucleico y usos de las mismas.
SG11202006457YA (en) 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
US20200405791A1 (en) * 2018-03-12 2020-12-31 Mayo Foundation For Medical Education And Research Using infectious nucleic acid to treat cancer
JP7602454B2 (ja) 2018-08-09 2024-12-18 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
CA3117924A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
CA3124524A1 (en) * 2019-01-04 2020-07-09 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use
US12209250B2 (en) * 2019-03-14 2025-01-28 Massachusetts Institute Of Technology Engineered Herpes Simplex Virus-1 (HSV-1) vectors and uses thereof
JP2022543610A (ja) * 2019-08-05 2022-10-13 ヴァイロジン バイオテック カナダ リミテッド 遺伝子改変エンテロウイルスベクター
CN114765990A (zh) * 2019-10-10 2022-07-19 昂克诺斯公司 双重病毒和双重溶瘤病毒以及治疗方法
EP4157456A4 (en) * 2020-05-29 2024-06-26 Oncorus, Inc. ENCAPSULATED RNA REPLIKONS AND METHODS OF USE
EP4164596A1 (en) * 2020-06-11 2023-04-19 eTheRNA Immunotherapies NV Lipid nanoparticles
US20230242994A1 (en) * 2020-07-10 2023-08-03 Shanghai Miran Biotech Co., Ltd. Fluorescent cross-linked rnase h mutant conjugate, mirna combination and application thereof
CA3204244A1 (en) * 2021-01-06 2022-07-14 Lorena Lerner Encapsulated rna polynucleotides and methods of use
CN113368261A (zh) * 2021-06-17 2021-09-10 苏州大学 一种非病毒载体及其制备方法与应用
WO2023069948A1 (en) 2021-10-18 2023-04-27 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
US20250304999A1 (en) * 2022-05-20 2025-10-02 Virogin Biotech Canada Ltd Genetically modified enterovirus vectors with enhanced genomic stability
JP7229412B1 (ja) 2022-06-14 2023-02-27 キユーピー株式会社 脂質ナノ粒子及びその製造方法
CN118634240A (zh) * 2022-06-27 2024-09-13 浙江大学 抗口腔肿瘤药物活性成分及其用途
KR20260043572A (ko) * 2024-09-24 2026-03-31 고려대학교 산학협력단 폐암 치료를 위한 페메트렉시드-기능화 종양 미세환경 표적 흡입용 약물전달시스템

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004274860A1 (en) * 2003-05-28 2005-03-31 Wisconsin Alumni Research Foundation Recombinant influenza vectors with a polII promoter and ribozymes
DK1668025T3 (da) * 2003-09-26 2014-08-25 Novartis Ag Seneca Valley-virusbaserede præparater og fremgangsmåder til behandling af sygdom
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
GB0810912D0 (en) * 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
DK2346995T3 (en) * 2008-09-26 2019-02-11 Tocagen Inc GENETERIVE VECTORS AND CYTOSINDEAMINASES
CA2782366A1 (en) * 2009-12-16 2011-07-14 Opko Curna, Llc Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
WO2013083753A2 (en) * 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
WO2013156989A1 (en) * 2012-04-18 2013-10-24 Ramot At Tel-Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
WO2014171526A1 (ja) * 2013-04-17 2014-10-23 国立大学法人九州大学 遺伝子改変コクサッキーウイルス
US10513711B2 (en) * 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
HK1246183A1 (zh) * 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017096201A1 (en) * 2015-12-02 2017-06-08 Memorial Sloan-Kettering Cancer Center Seneca valley virus (svv) cellular receptor targeted oncotherapy

Also Published As

Publication number Publication date
BR112020000839A2 (pt) 2020-07-21
JP2020530778A (ja) 2020-10-29
EP3652325A4 (en) 2021-09-15
SG11202000312UA (en) 2020-02-27
IL271969A (en) 2020-02-27
CN111212914A (zh) 2020-05-29
KR20200036873A (ko) 2020-04-07
EP3652325A1 (en) 2020-05-20
CA3069821A1 (en) 2019-01-17
US20200224220A1 (en) 2020-07-16
AU2018301701A1 (en) 2020-02-27
JP2023165916A (ja) 2023-11-17
WO2019014623A1 (en) 2019-01-17
MX2020000495A (es) 2020-08-20

Similar Documents

Publication Publication Date Title
JP2020530778A5 (cg-RX-API-DMAC7.html)
JP2023165916A (ja) カプセル封入ポリヌクレオチド及び使用方法
ES2256265T3 (es) Vectores de parvovirus duplicados.
RU2020108004A (ru) Онколитические вирусные векторы и их применение
JP2022516318A5 (cg-RX-API-DMAC7.html)
JP2020532951A5 (cg-RX-API-DMAC7.html)
Wang et al. State-of-the-art human gene therapy: part I. Gene delivery technologies
JP2024503623A5 (cg-RX-API-DMAC7.html)
AU2019381698A1 (en) Encapsulated polynucleotides and methods of use
RU2016120618A (ru) Онколитический hsv-вектор
WO2020113151A1 (en) Hsv vector with reduced neurotoxicity
Parsel et al. Nucleic acid targeting: towards personalized therapy for head and neck cancer
Chen et al. Oncolytic Virotherapy in Solid Tumors: A Current Review: C. Chen et al.
Zhao et al. Challenges and strategies toward oncolytic virotherapy for leptomeningeal metastasis
JP2024512053A (ja) 転写及び翻訳の二重調節を受ける腫瘍溶解性単純ヘルペスウイルスベクター
Zhang et al. Oncolytic virotherapy for malignant tumor: current clinical status
Ning et al. Current status of gene therapy for brain tumors
Pazarentzos et al. Anticancer gene transfer for cancer gene therapy
Calinescu et al. Harnessing Human Stem Cells for the Treatment of Glioblastoma–Twenty Year Perspective–Review of Preclinical and Clinical Studies: 2000–2020
RU2021123104A (ru) Инкапсулированные полинуклеотиды рнк и способы их применения
HK40029850A (en) Encapsulated polynucleotides and methods of use
CN117065052A (zh) 递送自复制rna分子的方法
CN102373232A (zh) 一种新型组织特异性小环载体hIFNγ基因治疗药物
US20190202866A1 (en) Viral nanoparticles and methods of use thereof
HK40058843A (en) Hsv vector with reduced neurotoxicity